Back to results
US 2014/0228289 A1Published application
Modified and stabilized gdf propeptides and uses thereof
AssigneeWyeth
InventorsNeil M. Wolfman, Soo Peang Khor, Kathleen N. Tomkinson
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeWyeth
InventorsNeil M. Wolfman, Soo Peang Khor, Kathleen N. Tomkinson
Estimating the term…
Modified and stabilized propeptides of Growth Differentiation Factor proteins, such as GDF-8 and Bone Morphogenetic Protein-11, are disclosed. Also disclosed are methods for making and using the modified propeptides to prevent or treat human or animal disorders in which an increase in muscle tissue would be therapeutically beneficial. Such disorders include muscle or neuromuscular disorders (such as amyotrophic lateral sclerosis, muscular dystrophy, muscle atrophy, congestive obstructive pulmonary disease, muscle wasting syndrome, sarcopenia, or cachexia), metabolic diseases or disorders (such as such as type 2 diabetes, noninsulin-dependent diabetes mellitus, hyperglycemia, or obesity), adipose tissue disorders (such as obesity), and bone degenerative diseases (such as osteoporosis).
1-118. (canceled)
A modified GDF-8 propeptide polypeptide comprising a mutation at a corresponding position in the amino acid sequence of SEQ ID NO:1 selected from among the group consisting of Arg-45, Gln-46, Lys-49, Ser-50, Arg-52, Ile-53, Lys-63, Leu-64, Arg-65, Leu-66, Arg-98, and Asp-99.
The modified GDF-8 propeptide polypeptide of claim 1, wherein the mutation is a substitution mutation with any other amino acid.
A nucleic acid encoding the modified GDF-8 propeptide polypeptide of claim 1.
A method of treating a disorder by administering a therapeutically effective amount of the modified GDF-8 propeptide of claim 1, wherein said disorder is selected from among the group consisting of a muscular disorder, a neuromuscular disorder, a metabolic disorder, an adipose tissue disorder, and a bone disorder.
Dependencies are inferred from the claim text.